Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Non-Current Deffered Revenue (2023 - 2024)

Immunome's Non-Current Deffered Revenue history spans 2 years, with the latest figure at $2.2 million for Q1 2024.

  • For Q1 2024, Non-Current Deffered Revenue fell 76.56% year-over-year to $2.2 million; the TTM value through Mar 2024 reached $2.2 million, down 76.56%, while the annual FY2023 figure was $5.5 million, N/A changed from the prior year.
  • Non-Current Deffered Revenue reached $2.2 million in Q1 2024 per IMNM's latest filing, down from $5.5 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $9.4 million in Q1 2023 to a low of $2.2 million in Q1 2024.